Cancer Stocks

Shares of bluebird bio Inc (NASDAQ: BLUE) have gained 75 percent since the start of 2017, which prompted analysts at BTIG to downgrade the biotech company at the forefront of fighting against cancer. BTIG's Dane Leone downgrades Bluebird's stock rating from Buy to Neutral as many of the bullish...

Bluebird bio Inc (NASDAQ: BLUE), a clinical-stage biotechnology company that focuses on developing gene therapies for severe diseases and cancer, reported on Monday top-line results from a study called Starbeam. Starbeam explores the company's LentiD investigational gene therapy for the treatment...

Shares of Clovis Oncology Inc (NASDAQ: CLVS), a biopharmaceutical company that develops an ovarian cancer drug called Rubraca (rucaparib), surged higher by 45 percent early Monday morning after the company released encouraging late-stage data from an ongoing trial called ARIEL3. Clovis' ARIEL3 is a...

Michael Yee of RBC Capital Markets reiterated an Outperform rating on Kite Pharma Inc (NASDAQ: KITE) with a price target boosted to $95 from a previous $85. According to Yee, competition from Novartis AG (ADR)'s (NYSE: NVS) CTL019 CAR-T isn't too concerning as Novartis' prior studies...